NEONC Secures $50M Global Deal for Brain Cancer Therapies with Quasar Investment
New to The Street TVJuly 29, 20251 min1,023 views
6 connections·6 entities in this video→Strategic Partnership and Investment
- 🤝 NEONC Technologies (NTHI) has finalized a significant $50 million strategic partnership with Quasar Investment.
- 💰 The deal comprises a $35 million equity investment at $25 per share, noted as a substantial premium, and an additional $15 million earmarked for clinical trials and expansion.
Global Expansion and New Entities
- 🌍 NEONC is set to launch two new entities, Neuromina and Neuro Cure, based in Abu Dhabi.
- 🇦🇪 These entities will accelerate clinical trials and build infrastructure within the UAE and the broader MENA region.
Advancing Brain Cancer Therapies
- 🧠 The partnership aims to expedite the development of NEONC's brain cancer treatments, NEO100 and NEO212.
- 🚀 Both therapies have received FDA Fast Track status, indicating potential for accelerated review and approval.
- 📈 The investment will support Phase 2b clinical trials for these promising oncology innovations.
Investor Outlook
- 📈 This milestone is presented as a signal of strong global momentum for NEONC in the biotech sector.
- 💡 The deal suggests significant potential upside for investors in oncology innovation.
Knowledge graph6 entities · 6 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
6 entities
Chapters1 moments
Key Moments
Transcript4 segments
Full Transcript
Topics14 themes
What’s Discussed
NEONC TechnologiesNTHIQuasar InvestmentBrain Cancer TherapiesNEO100NEO212NeurominaNeuro CureAbu DhabiMENA RegionClinical TrialsFDA Fast TrackBiotech InvestingOncology Innovation
Smart Objects6 · 6 links
Companies· 4
Products· 2